ClinicalTrials.gg
RecruitingNCT07547553Updated Jun 16, 2026

A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC

A Phase 1/2 interventional study of Will receive HH-009 injection 20 mg/kg, Q3W and Will receive HH-009 injection 30 mg/kg, Q3W in Advanced or Unresectable Hepatocellular Carcinoma (HCC), sponsored by Huahui Health. Recruiting at 21 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Huahui Health · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 1,314 studies in Carcinoma, Hepatocellular with a site in China — 489 open to participants now, 561 under way, 70 of them phase 3. Carcinoma, Hepatocellular · China.

Planned enrollment
779th of 1,038
30 · median 77
Started
2026
with 97 others
Phase 1/2
89 of 1,314
33 open now
Primary completion
2028-10
later than 483 of 560 live
Registered
1,241st of 1,314
by date

Among the 1,314 studies in Carcinoma, Hepatocellular with a site in China, this one is the 779th largest by planned enrollment of the 1,038 interventional ones that give a count, is one of 98 that started in 2026, is one of 89 in phase 1/2, reaches primary completion later than 483 of the 560 other live ones, and was the 1,241st registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,067 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

489 of the 1,314 studies in Carcinoma, Hepatocellular with a site in China are open now. Recruiting first, the newest first:

484 more — sign in →

All 489 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 742 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 252 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,314 studies in Carcinoma, Hepatocellular with a site in China, or all of them as a file.
02

Study summary

This is a randomized, open-label, multicenter Phase Ib/II registration trial designed to evaluate the efficacy and safety of HH-009 in patients with FGF19-positive hepatocellular carcinoma (HCC). The study will also assess pharmacokinetics, pharmacodynamics, immunogenicity, and exploratory biomarkers.

Approximately 30 patients with FGF19-positive advanced HCC will be enrolled. Eligible participants will be randomized 1:1 to receive HH-009 at either 20 mg/kg or 30 mg/kg Q3W as monotherapy. Treatment will continue until disease progression, unacceptable toxicity, initiation of new anticancer therapy, study withdrawal, completion of two years of treatment, loss to follow-up, death, or other protocol-specified reasons, whichever occurs first.

Read the detailed description

This study is a randomized, open-label, multi-center Phase Ib/II registration clinical trial. The study aims to evaluate the efficacy and safety of HH-009 in participants with FGF19-positive HCC; meanwhile, PK, PD, and immunogenicity profiles will be analyzed, and relevant biomarkers will be explored.

Approximately 30 participants with advanced HCC who are FGF19-positive and have progressed after systemic therapy failure will be enrolled. Eligible participants meeting inclusion / exclusion criteria will be randomly assigned in a 1:1 ratio to two dose groups: HH-009 20 mg/kg or 30 mg/kg.

Eligible participants will receive HH-009 monotherapy at a dose of 20 mg/kg or 30 mg/kg according to the randomly assigned HH-009 dose group, administered once every 3 weeks (Q3W), until progressive disease, intolerable toxicity (except when tolerability is restored after dose adjustment), initiation of new anticancer therapy, loss to follow-up, death, withdrawal from the study, completion of 2 years of study treatment, or any other reason (whichever occurs first).

03

Conditions studied

  • Advanced or Unresectable Hepatocellular Carcinoma (HCC)

Keywords

  • Hepatocellular Carcinoma
  • FGF19 positive
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary participation in a clinical trial and signed .
  • Ages 18 to 75 years (inclusive of the boundaries), male or female.
  • Participants with advanced or unresectable HCC confirmed by pathological histology or diagnosed in accordance with the clinical criteria specified in the National Health Commission guidelines, with the following additional requirements:

    • Participants with HCC who have experienced progressive disease after prio systemic therapy;
    • Tumor tissue IHC testing for FGF19 was positive (confirmed by central laboratory);
    • class A or class B (Child-Pugh score ≤7) ;
    • Barcelona Clinic Liver Cancer (BCLC) stage B or C
  • score 0 or 1
  • Have at least one according to v1.1.
  • ≥ 12 weeks.
  • Adequate organ and bone marrow function.
  • Participants with infection, whose HCV-RNA levels are above the lower limit of detection at the study site, are eligible if antiviral therapy is initiated prior to the first dose administration.
  • Participants with virus (HBV) infection must have HBV DNA \< 104 cps/mL or 2,000 IU/mL.
  • Participants (including partners of the male participants) are willing to use effective from the screening period until 6 months after the last product administration.

Exclusion criteria

Exclusion Criteria:

  • Participated in another clinical trial of drugs or investigational medical devices within 28 days prior to the first dose; or received anticancer treatment within the past 4 weeks before the first dose, or within five half-lives of the drug (whichever is shorter), including but not limited to chemotherapy, radiotherapy (allowing palliative radiotherapy completed at least two weeks prior to investigational product administration), targeted therapy, immunotherapy, or endocrine therapy; or received traditional Chinese medicine with anticancer indications within one week before the first dose.
  • The previous antitumor treatment-related toxicity has not yet recovered to ≤ grade 1 or baseline level
  • Previously received FGFR inhibitors, including FGFR4 inhibitors and pan-FGFR inhibitors.
  • Undergone major surgery (except ) within 4 weeks prior to the first study dose of the investigational product, or surgical wounds not fully healed.
  • Presence of moderate to large pleural or ascitic effusion accompanied by clinical symptoms, uncontrolled, or requiring repeated drainage.
  • Participants with active or a history of diseases that are likely to recur (including systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disorders, multiple sclerosis, vasculitis, glomerulonephritis, etc.), or participants at high risk (e.g., participants who have undergone organ transplantation and require therapy).
  • Participants with a known history of other within 5 years prior to enrollment.
  • (meningeal) , active
  • Participants with known active tuberculosis or suspected active tuberculosis, or participants with active pneumonia requiring treatment.
  • History of cardiovascular and cerebrovascular diseases.
  • Systemic treatment with or other immunosuppressive drugs within 14 days prior to the first dose.
  • History of (HIV) infection, or active infection requiring systemic treatment for more than 7 consecutive days within 14 days prior to the first dose administration.
  • Co-infection with and
  • Blood transfusion, treatment with granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, thrombopoietin, or erythropoietin initiated within 2 weeks prior to the first dose.
  • Bile acid-modulating medications that cannot be discontinued within 3 days prior to the first dose or within 5 half-lives of the drug (whichever is longer).
  • History of severe allergic reactions to other therapeutic antibody drugs; or known allergy to multiple substances or suffering from severe allergic diseases.
  • Pregnant or lactating females, or those with a positive blood pregnancy test.
  • Other severe, acute, or chronic medical or psychiatric conditions or laboratory abnormalities that, in the investigator's judgment, may increase the risk associated with study participation or may interfere with the interpretation of study results, or any other situation considered unsuitable for participation in this study.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    HH-009 20 mg/kg group

    Will receive HH-009 injection 20 mg/kg monotherapy, Q3W

    Drug: Will receive HH-009 injection 20 mg/kg, Q3W

  • Experimental
    HH-009 30 mg/kg group

    Will receive HH-009 injection 30 mg/kg monotherapy, Q3W

    Drug: Will receive HH-009 injection 30 mg/kg, Q3W

Interventions

  • DrugWill receive HH-009 injection 20 mg/kg, Q3W

    Will receive HH-009 injection 20 mg/kg monotherapy, Q3W

  • DrugWill receive HH-009 injection 30 mg/kg, Q3W

    Will receive HH-009 injection 20 mg/kg monotherapy, Q3W

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS assessed by investigators according to RECIST v1.1

    Time frame: Through study completion, up to 2 years

Secondary outcomes

  1. ORR

    Defined as the proportion of participants achieving complete response (CR) or partial response (PR)

    Time frame: Through study completion, up to 2 years

  2. DCR

    Defined as the proportion of participants achieving CR, PR, or SD

    Time frame: Through study completion, up to 2 years

  3. Time to progression (TTP)

    Time frame: Through study completion, up to 2 years

  4. DOR

    Time frame: Through study completion, up to 2 years

  5. Time to Response (TTR)

    Time frame: Through study completion, up to 2 years

  6. overall survival (OS)

    Time frame: Through study completion, up to 3 years

  7. Incidence of all AE, TEAE, and SAE

    Incidence, relationship to the investigational drug, and severity of all AE, TEAE, and SAE.

    Time frame: During study period

  8. Area Under the Plasma Concentration Versus Time Curve (AUC)

    AUC of HH-009 in plasma

    Time frame: Through study completion, up to 2 years

  9. Maximum Plasma Concentration (Cmax)

    Cmax of HH-009 in plasma

    Time frame: Through study completion, up to 2 years

  10. Time to Reach Maximum Plasma Concentration (Tmax)

    Tmax of HH-009 in plasma

    Time frame: Through study completion, up to 2 years

  11. Apparent Terminal Elimination Half-life (T1/2)

    T1/2 of HH-009 in plasma

    Time frame: Through study completion, up to 2 years

Other outcomes

  1. Dynamic changes in FGF19 in blood

    Changes in selected PD markers before and after treatment.

    Time frame: Through study completion, up to 2 years

  2. The incidence and changes in ADA.

    Time frame: Through study completion, up to 2 years.

07

Study locations

3 of 21 sites recruiting
  • The First Affiliated Hospital of Bengbu Medical University
    Bengbu, Anhui, China
    Not yet recruiting
  • Anhui Provincial Hospital
    Hefei, Anhui, China
    Not yet recruiting
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui, China
    Not yet recruiting
  • Capital Medical University Affiliated Beijing Ditan Hospital
    Beijing, Beijing Municipality, China
    Recruiting
  • The Fifth Medical Center of the PLA General Hospital
    Beijing, Beijing Municipality, China
    Not yet recruiting
  • Mengchao Hepatobiliary Hospital of Fujian Medical University
    Fuzhou, Fujian, China
    Not yet recruiting
  • NanFang Hospital of Southern Medical University
    Guangzhou, Guangdong, China
    Not yet recruiting
  • Affiliated Tumor Hospital of Guangxi Medical University
    Nanning, Guangxi, China
    Not yet recruiting
  • Guangxi Zhuang Autonomous Region People's Hospital
    Nanning, Guangxi, China
    Not yet recruiting
  • Harbin Medical University Affiliated Cancer Hospital
    Harbin, Heilongjiang, China
    Not yet recruiting
  • Henan Provincial Cancer Hospital
    Zhengzhou, Henan, China
    Not yet recruiting
  • The First Affiliated Hospital of Henan Medical University
    Zhengzhou, Henan, China
    Recruiting
  • Wells Prince Hospital of The Chinese University of Hong Kong
    Hong Kong, Hong Kong, China
    Not yet recruiting
  • Nanjing Tianyinshan Hospital
    Nanjing, Jiangsu, China
    Recruiting
  • Jiangxi Cancer Hospital
    Nanchang, Jiangxi, China
    Not yet recruiting
  • Jilin University First Hospital
    Changchun, Jilin, China
    Not yet recruiting
  • Liaoning Cancer Hospital
    Shenyang, Liaoning, China
    Not yet recruiting
  • Shanghai Gaobo Tumor Hospital
    Shanghai, Shanghai Municipality, China
    Not yet recruiting
  • Zhongshan Hospital Affiliated to Fudan University
    Shanghai, Shanghai Municipality, China
    Not yet recruiting
  • Tianjin Medical University Cancer Hospital
    Tianjin, Tianjin Municipality, China
    Not yet recruiting
  • Shao Yi Fu Hospital, Affiliated to the School of Medicine of Zhejiang University
    Hangzhou, Zhejiang, China
    Not yet recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Oct 2028, 29 months after the start.

Of 72 industry-sponsored phase 1/2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 74. This study's planned 29 months is below that.

Counting every sponsor, half of 136 studies reached it within 53 months; a quarter within 38 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2026
First posted
Apr 23, 2026
StartActual
May 19, 2026
Primary completionEst.
Oct 30, 2028
CompletionEst.
Oct 30, 2028
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07547553
Lead sponsor
Huahui Health
Responsible party
Sponsor
First posted
Apr 23, 2026
Start date
May 19, 2026
Primary completion
Oct 30, 2028 (estimated)
Completion
Oct 30, 2028 (estimated)
Last update
Jun 16, 2026

Study contacts

Xiyu Zhang PM
Contact
zhangxiyu@hhhbio.com
18701650516

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion